Labcorp Appoints Dr. Paul Rothman to Board of Directors

Health system executive brings three decades of medical enterprise experience to Labcorp BURLINGTON, N.C. , June 7, 2023 /PRNewswire/ --  Labcorp (NYSE: LH), a leading global life sciences company, today announced the appointment of Dr. Paul Rothman to its Board of Directors as an independent

7 ways to improve men’s health this June

In June, we celebrate Men’s Health Awareness, so it’s a great time to think about some important steps men can take to put their health first. Compared with women, men are at increased risk for a number of conditions, including heart disease, cancer, respiratory disease and more.

Comparison of immune microenvironment between primary and metastatic breast tumors

Rachel Smith, PhD

Dr. Rachel Smith is a research and development scientist for Labcorp Biopharmaceutical CMC Services. Her background is in mass spectrometry, and in addition to developing methods for LC-MS analysis of biotherapeutics, she leads the forced degradation and formulation development teams. Her particular focus has been on the development of workflows for intact and middle-up LC-MS characterization of mAbs and derivative fusion proteins, but she is experienced in all of the LC-MS biopharmaceutical characterization methods offered by Labcorp Biopharmaceutical CMC Services.

Warren Rowland

Warren Rowland joined Labcorp Biopharmaceutical CMC Services in 2010. He has more than 20 years of experience in drug development spanning both small and large molecules within research and development/GLP/GMP environments with experience in large pharmaceutical companies and contract research organizations. He holds a BA in chemistry from Monmouth College.

Colin Guy, PhD

Dr. Colin Guy received his PhD (biochemistry) from the University of Nottingham in 2006, and following postdoctoral studies, he joined Labcorp Drug Development in 2010. He has a broad range of experience within the biochemistry field, including in liquid chromatography, capillary and gel electrophoresis and ligand binding assays.

Tobey Gooding

Tobey Gooding began his career more than 20 years ago at Eli Lilly and Company in Indianapolis after graduating with a BA in chemistry and biology from Anderson University. There, as an analytical scientist, he gained experience in both immunochemistry and traditional protein chemistry techniques and supported bulk and parenteral manufacturing, cleaning validation and analytical development.

Henry Fisher, PhD

In his role at Labcorp Drug Development, Dr. Henry Fisher is responsible for working closely with clients to develop LC-MS methods for various modalities for both characterization and GMP validation. His primary expertise is biopharmaceutical characterization by peptide mapping, multi-attribute monitoring and host-cell protein analysis but has experience in a range of LC-MS techniques for characterization of biologics. Much of Henry’s work at Labcorp Biopharmaceutical CMC Services is contributing the innovation efforts to bring new LC-MS capabilities into the business.

Leonard Bell, PhD

Originally a chemistry graduate, Dr. Leonard Bell initially worked in the industry as a peptide chemist. He then returned to university for his MSc (biomolecular technology) and PhD (“Interaction of Metal Ions and the β-Amyloid Peptide”). He subsequently returned to the industry after his postdoctoral work (“Peptides That Protect Cardiomyocytes From Anoxia and Reoxygenation”) and joined Labcorp Drug Development’s Biopharmaceutical CMC Services, specializing in large molecules.

Heather Watson

Heather Watson has 22 years of experience in the pharmaceutical and biotech industry, 14 of those in the CRO environment. Her areas of expertise include method development, validation and sample analysis of PK, PD and ADA (inclusive of NAb) methods, supporting both preclinical and clinical programs. She has experience with a variety of drug molecules including but not limited to ADCs, bi- or tri-specific Abs, biosimilars and gene therapies.